| --- | --- | --- | |-------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The Power of Plants | | | | Q2 2022 INVESTOR PRESENTATION | | | Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "ant ...

Calyxt, Inc. (CLXT) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and Chief Executive Officer Conference Call Participants Bobby Burleson - Canaccord Amit Dayal - H.C. Wainwright Brian Wright - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calyxt’s First Quarter 2022 Earnings Result Conference Call and Webcast. [Operator Instructions] This conference is ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock (0.0001 par value) CLXT The NASDAQ Global Market Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran ...

| --- | --- | --- | --- | |--------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4Q and FY 2021 Earnings | | | | | Results Conference Call and Webcast | | | | | MARCH 3, 2022 | | | | Management on Today's Call Michael A. Carr President and Chief Executive Officer Bill Koschak Chief Financial Officer © calyxt 2 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the ...

Calyxt, Inc. (CLXT) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and CEO Conference Call Participants Laurence Alexander - Jefferies Bobby Burleson - Canaccord Brian Wright - ROTH Capital Partners Amit Dayal - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calyxt Fourth Quarter and Full Year 2021 Earnings Conference -- Result Conference Call and Webcast. Dur ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38161 Calyxt, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1967997 (State or other juri ...

Financial Data and Key Metrics Changes - Revenue for Q3 2021 was $7.8 million, an increase of $2.5 million or 48% from Q3 2020, driven by the volume and mix of products sold [58] - Gross profit was negative $0.5 million or negative 7% of revenue in Q3 2021, compared to negative $1.8 million or negative 35% of revenue in Q3 2020 [58] - Net loss improved to $7.3 million in Q3 2021, a reduction of $2.2 million or 23% from Q3 2020 [62] - Adjusted EBITDA loss was $6.9 million in Q3 2021, essentially flat compared to Q3 2020 [62] Business Line Data and Key Metrics Changes - The company transitioned from selling oil and meal to grain, which positively impacted revenue and gross profit margins [58][59] - Adjusted gross profit was negative $2.7 million or negative 35% of revenue in Q3 2021, compared to negative $1.3 million or negative 24% of revenue in Q3 2020, indicating a shift in product mix [60] Market Data and Key Metrics Changes - The company is targeting diverse end markets including nutraceuticals, cosmeceuticals, pharmaceuticals, advanced materials, and chemicals, which are increasingly seeking sustainable solutions [45][70] - The Boston Consulting Group estimates that nature-derived products will impact $30 trillion of the global economy over the next 30 years, driven by sustainability and decarbonization goals [23] Company Strategy and Development Direction - The company announced a strategic initiative to expand its offerings to provide innovative, sustainably produced plant-based solutions [9] - The PlantSpring Technology Platform and BioFactory production system are central to the company's strategy, enabling faster and more sustainable production of complex plant-based chemistries [42][35] - The company aims to develop 2 to 4 new compounds per year, targeting significant revenue growth from these products [51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet sustainability and financial targets for customers, positioning itself as a key player in plant-based synthetic biology [68] - The regulatory environment for new end-markets is expected to be less burdensome compared to traditional agricultural products, which may facilitate quicker market entry [74] Other Important Information - The company ended Q3 2021 with cash and cash equivalents of $14.9 million [18] - A research collaboration was announced with a leading global food ingredient manufacturer to develop a sustainable alternative to palm oil [16] - The company has initiated a $50 million ATM share issuance program, raising approximately $3.7 million to date [64] Q&A Session Summary Question: Regulatory issues around plant trait development vs. BioFactory products - Management indicated that the regulatory requirements for new end-markets are less onerous and costly compared to traditional agricultural products [74] Question: Revenue expectations for BioFactory products - Management clarified that the expected $1 million in the first year includes both development and product revenue [75][77] Question: Liquidity comments and runway - Management confirmed that the liquidity runway includes the recent $3.7 million raised [78] Question: Collaboration with global food manufacturer - Management confirmed that the collaboration is based on legacy technology but aligns with the new PlantSpring initiative [96] Question: Proof-of-concept compounds development - Management stated that the proof-of-concept compounds were developed organically to showcase the capabilities of the PlantSpring platform [94] Question: Capacity of the bioreactor - Management confirmed that the initial pilot bioreactor has a capacity of 200 liters [95] Question: Expected operating expenses for 2022 - Management indicated that cash operating expenses for 2022 are expected to be similar to 2021, with a slight increase [98]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock (0.0001 par value) CLXT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio ...

Calyxt, Inc. (CLXT) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Cameron Willis - Assistant Vice President of Argot Partners, Investor Relations, Calyxt Yves Ribeill - Executive Chair of the Board Michael Carr - President & Chief Executive Officer Bill Koschak - Chief Financial Officer Conference Call Participants Laurence Alexander - Jefferies Bob Burleson - Canaccord Genuity Sameer Joshi - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38161 Calyxt, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |--------------------- ...